TheraRadar
Clinical-Stage Companies / FORUM

FORUM

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 7/1/2015

17
Total Trials
6
Phase 3
4
Phase 2
0
Recruiting
143
Score

Pipeline by Phase

Phase 3
6
Phase 2
4
Phase 1
7

Therapeutic Focus

Alzheimer's Disease Schizophrenia Dementia Central Nervous System Diseases Impaired Cognition

Clinical Trials (17)

NCT01969123 Phase 3 TERMINATED

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Started: 10/1/2013

NCT02004392 Phase 3 TERMINATED

Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025

Started: 6/1/2014

NCT01714713 Phase 3 COMPLETED

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Started: 6/1/2013

NCT01714661 Phase 3 COMPLETED

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Started: 10/1/2012

NCT01716975 Phase 3 COMPLETED

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Started: 10/1/2012

NCT01969136 Phase 3 TERMINATED

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Started: 10/1/2013

NCT02246075 Phase 2 WITHDRAWN

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

Started: 7/1/2015

NCT01073228 Phase 2 COMPLETED

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Started: 4/1/2010

NCT00968851 Phase 2 COMPLETED

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Started: 12/1/2009

NCT01661673 Phase 2 COMPLETED

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Started: 11/1/2012

NCT01984723 Phase 1 COMPLETED

EVP-6124 Renal Impairment Study

Started: 6/1/2013

NCT01984736 Phase 1 COMPLETED

EVP-6124 Hepatic Impairment Study

Started: 6/1/2013

NCT02037074 Phase 1 COMPLETED

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Started: 6/1/2014

NCT02001389 Phase 1 COMPLETED

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

Started: 10/1/2013

NCT01487135 Phase 1 COMPLETED

Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects

Started: 12/1/2011

NCT01556763 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Started: 4/1/2008

NCT00766363 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Started: 10/1/2008

Drug Candidates

Drug: EVP-6124 Placebo EVP-6124 Experimental: EVP-6124 Drug: EVP-6308 EVP-6308 Moxifloxacin EVP-0962 EVP-6124 (0.3 mg/day) EVP-6124 (1.0 mg/day)
Activity Status: Inactive
Last Trial Started: 7/1/2015
Last Trial Ended: 8/1/2017
Trials (12 months): 0
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.